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The heme protein myeloperoxidase (MPO) contributes criti-
cally to O2-dependent neutrophil antimicrobial activity. Two
Japanese adults were identified with inherited MPO deficiency
because ofmutations at Arg-499 or Gly-501, conserved residues
near the proximal histidine in the heme pocket. Because of the
proximity of these residues to a critical histidine in the heme
pocket, we examined the biosynthesis, function, and spectral
properties of the peroxidase stably expressed in human embry-
onic kidney cells. Biosynthesis of normal MPO by human
embryonic kidney cells faithfully mirrored events previously
identified in cells expressing endogenousMPO.Mutant apopro-
MPO was 90 kDa and interacted normally with the molecular
chaperones ERp57, calreticulin, and calnexin in the endoplas-
mic reticulum. However, mutant precursors were not proteo-
lytically processed into subunits of MPO, although secretion of
the unprocessed precursors occurred normally. Although
-[14C]aminolevulinic acid incorporation demonstrated forma-
tion of pro-MPO in bothmutants, neither protein was enzymat-
ically active. The Soret band for each mutant was shifted from
the normal 430 to412 nm, confirming that hemewas incorpo-
rated but suggesting that the number of covalent bonds or other
structural aspects of the heme pocket were disrupted by the
mutations. These studies demonstrate that despite heme incor-
poration,mutations in the heme environs compromised the oxi-
dizing potential of MPO.
Phagocytes contribute significantly to human innate immu-
nity, and polymorphonuclear neutrophils (PMN)2 are the pre-
dominant granulocyte in the circulation. When PMN are defi-
cient in number or function, normal antimicrobial action is
severely compromised, resulting in increased morbidity and
mortality from infection. Well suited for the wide diversity of
potential microbial challenges, PMN possess a broad array of
responses bywhich to contain, control, kill, and degrademicro-
organisms, both in the phagosome and within the immediate
cellular environs. These defenses include degradative and anti-
microbial proteins, fabricated duringmyeloid development and
stored within the granules, as well as reactive oxygen and nitro-
gen species generated de novo specifically in response to inva-
sion.None of these elements functions alone, but rather there is
extensive and overlapping collaborations within the context of
the phagosome.
Themost extensively studied example of the synergistic anti-
microbial systems within human PMN is themyeloperoxidase-
H2O2-halide system (1). PMN simultaneously activate the nor-
mally dormantNADPHoxidase and release granule contents in
response to stimulation. The H2O2 produced by the multicom-
ponent phagocyteNADPHoxidase (2) converts the azurophilic
granule protein myeloperoxidase (MPO) from its resting state
into compound I, a transient intermediate with potent oxidiz-
ing properties, which in turn oxidizes Cl to Cl, thereby gen-
erating the potent antimicrobial agent HOCl (3). In addition to
HOCl, chloramines and other longer lived products of the
MPO-H2O2-halide system have been implicated in mediating
cytotoxicity to a broad array ofmicroorganisms aswell asmam-
malian proteins and cells (4–10). In its capacity as a peroxidase,
the activity ofMPOdepends on a normal heme group, which in
the case ofMPO is a ferric protoporphyrin IX covalently linked
to the protein backbone (11, 12). Data from the crystal structure
of native human MPO indicate that the heme group stably
interacts with the protein backbone via three covalent bonds
and eight hydrogen bonds (11). Structural features unique to
the heme group ofMPOmake it the onlymember of the animal
peroxidase family capable of oxidizing chloride and thus gener-
ating HOCl, at physiologic pH (13–15).
Significant insights into the normal biosynthesis, structure,
and function of MPO have been derived from studies of the
functional impact of inherited mutations (reviewed in Ref. 6
and see Refs. 16–20). To date, none of the previously charac-
terized genotypes has directly involved the region around the
* This work was supported by National Institutes of Health Grant HL 53592
and a Merit Review from Veterans Affairs (to W. M. N.). The costs of publi-
cation of this article were defrayed in part by the payment of page charges.
This article must therefore be hereby marked “advertisement” in accord-
ance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence should be addressed: Inflammation Program,
and Dept. of Medicine, Roy J. and Lucille A. Carver College of Medicine,
University of Iowa, D160 MTF, 2501 Crosspark Road, Coralville, IA 52241.
Tel.: 319-335-4278; Fax: 319-335-4194; E-mail: william-nauseef@
uiowa.edu.
2 The abbreviations used are: PMN, polymorphonuclear neutrophil; MPO,
myeloperoxidase; HEK, human embryonic kidney; PIPES, 1,4-piperazinedi-
ethanesulfonic acid; EPO, eosinophil peroxidase; LPO, lactoperoxidase;
TPO, thyroid peroxidase; ER, endoplasmic reticulum; CRT, calreticulin; CLN,
calnexin.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 282, NO. 38, pp. 27994 –28003, September 21, 2007
Printed in the U.S.A.
27994 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282 • NUMBER 38 • SEPTEMBER 21, 2007
This is an Open Access article under the CC BY license.
heme group of MPO. However, missense mutations at residue
5013 (glycine to serine, G501S) and residue 499 (arginine to
cysteine, R499C) have been identified in twounrelated Japanese
individuals with inherited MPO deficiency (21, 22). We
describe here the structural and functional consequences
caused by G501S and R499C, two mutations adjacent to the
critical histidine 502 on the proximal side of the heme inMPO.
EXPERIMENTAL PROCEDURES
Materials—K562 erythroleukemia cells and human embryo-
nal kidney 293 (HEK) cells were obtained from American Type
Culture Collection (Manassas, VA), ATCC CCL 243 and CRL-
1573, respectively. Vectors pREP10 and pcDNA3.1 and antibi-
otics hygromycin and G-418 sulfate were obtained from
Invitrogen; [35S]methionine/cysteine (26.7  107 Bq/0.5 ml)
was from Amersham Biosciences. -[14C]Aminolevulinic acid
(45.7 mCi/mmol) was custom-made by PerkinElmer Life Sci-
ences. All tissue culture reagents were obtained from the Uni-
versity of IowaHybridoma Facility. Antibodies against calnexin
and ERp57 were obtained from StressGen Bioreagents (Ann
Arbor, MI). The monospecific rabbit antibody against human
myeloperoxidase was generated in our laboratory (23), as was
the rabbit antibody against human calreticulin (24), the latter
available commercially from Affinity Bioreagents (Golden,
CO). EndoglycosidaseH andN-glycosidase F fromChryseobac-
terium meningosepticum were obtained from Calbiochem.
Unless otherwise specified, all other reagents were purchased
from Sigma.
Molecular Modeling—Reasoning that the missense muta-
tions at residues 499 and 501 might adversely influence the
structure around the heme inMPO, we modeled the active site
of native and mutant forms of the protein. To that end, the
three-dimensional structure of human MPO protein was
retrieved from the protein data base (Protein Data Bank code
1D2V), and its heme-containing domain was subjected to sim-
plistic energy minimization. For all three structures, we per-
formed force field-based energy minimization of side chains in
proximity to the heme to gain insight into the geometry and
possible conformational changes of critical residues at the
atomic level. We considered the heme, iron, and bromide ions
and close proximity residues (Fig. 1). Mutant MPO structures
were derived from the native MPO crystal structure by the in
silico replacement of Arg-499 with cysteine and Gly-501 with
serine using a molecular modeling package (Molecular Opera-
tion Environment, version 2004.10, Chemical Computation
Group). The geometry of introduced residues of the mutant
forms in the active site was minimized using the CHARMM 22
force field (25). The hydrogen atoms were added to the struc-
tures of native and mutated MPO protein using CHARMM
HBUILD module, and their positions were further optimized.
Stably Transfected Cells Lines—K562 erythroleukemia cells
were maintained in RPMI 1640 medium with 10% fetal calf
serum, 2 mM L-glutamine, and penicillin/streptomycin at 37 °C
in an atmosphere of 5%CO2 (18). HEK cells weremaintained in
Dulbecco’s modified Eagle’s medium/Ham’s nutrient mixture
F-12 medium supplemented with 10% fetal calf serum, 100
units/ml penicillin, 100 g/ml streptomycin, 100 mM HEPES,
and 2 mM L-glutamine. Stably transfected cell lines expressing
G501S andR499Cwere created using the same approaches pre-
viously employed to analyze normal and specific mutants of
humanMPO (17). PCRwas used tomutate Gly-501 or Arg-499
in normal MPO cDNA for heterologous expression in human
cell lines that are devoid of endogenousMPO. The forward and
reverse primers for mutagenesis of Gly-501 were GCCTTC-
CGCTACAGCCACACCCTCA and TGAGGGTGTGGCTG-
TAGCGGAAGGC, respectively, with the mutated residue
indicated in boldface type, whereas primers ACCAATGCCT-
TCTGCTACGGCCACA and TGTGGCCGTAGCAGAAG-
GCATTGTT were used to create R499C. The presence of the
desired mutation and absence of unintentional mutations were
confirmed by sequencing the cDNAprior to transfection. Once
the sequence of the desiredmutant construct was confirmed, it
was cloned into the expression vector (pREP10 for K562 cells
and pcDNA3.1() for HEK cells). Stable transfectants were
cloned by limiting dilution and selected using hygromycin and
G-418 sulfate, respectively.
MPO Biosynthesis by Transfectants—Stable transfectants
were used for the expression of wild-type and mutant forms of
MPO (17, 18, 24, 26). Cells were maintained at low density in
media supplementedwith 2g/ml hemin for 24 hprior to label-
ing and placed in methionine-free RPMI medium supple-
mented with fetal calf serum and antibiotics for 1 h prior to
pulse labeling with [35S]methionine/cysteine. Cells were
labeled for the indicated period and then recovered or chased
by the addition of 1000-fold excess of cold methionine, before
solubilization for subsequent analysis.
MPO-related productswere immunoprecipitated using anti-
bodies against MPO, CRT, or CLN. Biosynthetically radiola-
beled MPO-related proteins in cell lysates or culture medium
were immunoprecipitatedwithmonospecific, polyclonal rabbit
anti-humanMPO (17, 18, 24, 26–31) separated by SDS-PAGE,
followed by autoradiography, and quantitated by direct meas-
urement of radioactivity using a PhosphorImager (Typhoon
9410, Amersham Biosciences).
MPO-related species that were associated with CRT or CLN
were recovered and quantitated using sequential immunopre-
cipitations (17, 24, 26). Cell lysates were immunoprecipitated
first with CRT or CLN antiserum under nondenaturing condi-
tions. The CRT- or CLN-associated proteins in the recovered
complex were released by heating in the presence of 2% SDS,
and the solutionwas cooled anddiluted 10-fold before proceed-
ing with the immunoprecipitation with MPO antiserum. CRT-
and CLN-associated MPO species were separated by SDS-
PAGE and quantitated using the PhosphorImager.
Heme acquisition was assessed by radiolabeling with
-[14C]aminolevulinic acid, a precursor in heme synthesis, as
done previously. Stable transfectants expressing normal or
mutant MPOwere cultured in the presence of -[14C]aminole-
vulinic acid overnight, followed by solubilization and immuno-
precipitation of the cell lysate or conditioned culture media
withMPO antibody, as described above. MPO species contain-
ing 14C were quantitated with the PhosphorImager.
3 Because considerations of MPO include the propeptide, our amino acid des-
ignations are 166 greater (for the 166 amino acids in the propeptide) than
those used by Fenna and co-workers (11, 53).
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MPO Activity—Four different assays were employed to
assess MPO activity. Peroxidase activity of the expressed wild-
type or mutant MPO was quantitated in two complementary
ways. Nontransfected cells, normal MPO transfectants, and
transfectants expressing mutant MPO were cultured in the
presence of 2 g/ml hemin for 48 h prior to recovery and solu-
bilization for determination of enzymatic activity. Peroxidase
activity was quantitated spectrophotometrically using o-diani-
sidine as a substrate (32). Peroxidase activity in cell lysates was
also assessed by in situ staining in a native polyacrylamide gel.
Duplicate samples were electrophoresed under nondenaturing
conditions into two 10% polyacrylamide gels containing 0.05%
(w/v) cetyltrimethylammonium bromide and 25% glycerol
(w/v) in the absence of a stacking gel. Samples were electro-
phoresed at constant voltage (100 V) toward the cathode until
the dye front was5mm from the bottom of the gel (5 h). To
avoid permanently staining the Scotch Brite pads with crystal
violet, we often electrophorese the dye front off the gel (800–
1000 V-h) when subsequently blotting native gels. One gel was
washed and stained with trimethylbenzidine to assess peroxi-
dase activity (33–35). The other gel was soaked in transfer
buffer for 1 h and then subjected to electroblotting to a nitro-
cellulose filter for 850 V-h. The resulting blot was blocked and
then processedwithMPO antiserum. By performing both anal-
yses in parallel, peroxidase activity could be assigned to a spe-
cific protein immunochemically related to MPO.
The greater amounts of mutant protein generated by HEK
transfectants made possible two additional assays that are spe-
cific for MPO.We quantitated the capacity of HEK cell lysates,
either wild-type or transfectants expressing normal or mutant
MPO, to consumeH2O2, using a H2O2 electrode andmodifica-
tion of a method described previously (36). In the presence of
chloride, H2O2 consumption by MPO reflected HOCl produc-
tion. The electrode (Apollo 4000,World Precision Instruments,
Sarasota, FL) was calibrated daily with dilutions of reagent
grade H2O2 (0–20 mM), with the concentrations of the H2O2
standard verified spectrophotometrically using 240  43.6
M1 cm1 (37). Cell lysates were added to known amounts of
H2O2 in the presence of taurine, to scavenge HOCl and thus
eliminate the possibility of its inactivation of the MPO (36),
and the rate of H2O2 consumption was measured polari-
graphically. Data are expressed as nanomoles H2O2 con-
sumed per min per cell eq.
The lysates were likewise assessed for MPO-specific chlori-
nating capacity using the taurine chloramine assay (36). HOCl
reacts with taurine to generate taurinemonochloramine, which
in turns reacts with 5-thio-2-nitrobenzoic acid to generate 5,5-
dithiobis(2-nitrobenzoic acid). The concentration of taurine
monochloramine measured spectrophotometrically, 412 
14.1 M1 cm1, and its loss were monitored as a reflection of
HOCl production. Lysates from wild-type or transfected cells
were used as the potential peroxidase source, and acetalde-
hyde-xanthine oxidase served as a source for generating oxi-
dants. Data are expressed as nanomoles of HOCl produced/
min. All assays were performed in triplicate, and each
experiment was performed at least three times. We confirmed
our findings in a more sensitive and specific assay forMPO-de-
pendent chloramine production that uses iodide-dependent
oxidation of 3,3,5,5-tetramethylbenzidine as substrate (38).
As little as 200 pM MPO can be detected using this assay.
Glycosidase Susceptibility of MPO-related Proteins—Modifi-
cations of the carbohydrate side chains on MPO-related pro-
teins were assessed by their relative susceptibility to endoglyco-
sidases as done previously with MPO endogenously expressed
in myeloid precursors (31, 39). MPO-related proteins were
immunoprecipitated from cell lysates or culture medium at
specified time points and treated with endoglycosidase H or
N-glycanase to digest high mannose or complex carbohydrate
side chains, respectively. Digested proteins and control immu-
noprecipitates were separated by SDS-PAGE and visualized by
autoradiography.
Spectroscopy—Just as the endogenous MPO synthesized by
myeloid precursors is largely compartmentalized into an intra-
cellular organelle (1), MPO expressed by HEK cells was stored
in membrane-bound organelles that could be recovered by dif-
ferential centrifugation.HEKcells (1–2.5 108)were collected,
treated with diisopropylfluorophosphate, washed, and resus-
pended in relaxation buffer (10 mM PIPES, 100 mM KCl, 3 mM
NaCl, 3.5 mM MgCl2, 1 mM ATP, pH 7.3) at 2  107/ml. Cells
were then disrupted by N2 cavitation (350 p.s.i.), and the cavi-
tate was collected in a volume of EGTA, pH 7.4, to achieve a
final concentration of 1.25 mM, using a method employed pre-
viously for recovering intact intracellular organelles from
human neutrophils (40) and cultured promyelocytic cell lines
(32). Unbroken cells and nuclei were removed by low speed
centrifugation, and the supernatant was centrifuged at
12,000  g for 20 min (4 °C) to recover a pellet enriched for
dense intracellular organelles, including those containing
MPO-related proteins. The pellet was resuspended in phos-
phate-buffered saline without calcium or magnesium, washed,
and lysed by three freeze-thaw cycles using vigorous pipetting.
Vigorous pipetting at each step was essential to maximize ves-
icle disruption. The clarified supernatant after pellet lysis was
scanned from 400 to 600 nm in a Lambda 40 spectrophotome-
ter (PerkinElmer Life Sciences). In addition, oxidation-reduc-
tion difference spectroscopywas performed, using dithionite to
reduce the lysate in the sample cuvette. The concentration of
normal MPO was calculated for oxidized samples using 430 
91 mM1 cm1 (41). For turbid samples reduced minus oxi-
dized difference spectra were obtained, and the concentration
was calculated using 473  75 mM1 cm1 (41). For assays
using mutant MPO, the same extinction coefficients were
employed to approximate the concentrations of G501S and
R499C.
RESULTS
Identification of MPO-deficient Subjects—As part of ongoing
studies of the prevalence of inherited MPO deficiency in Japan
(42), individuals with partial or complete deficiency were iden-
tified using automated flow hematocytochemistry to screen
large populations. Among these deficient individuals were two
with missense mutations in MPO, G501S, and R499C, that had
not been reported previously. In both cases, the individuals
were asymptomatic and had not suffered from frequent or
severe infectious complications, as described in the detailed
clinical reports (21, 22, 42).
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Predictions Derived from Molecular Modeling—Given the
availability of the crystal structure of human MPO (11), we
modeled the heme pocket of specific mutants at residues 499
and 501 for comparison with the native protein and to gain
insight into their potential impact on MPO enzymatic activity.
The iron ion in native MPO has six coordination sites as fol-
lows: four sites are mediated by pyrrole nitrogen atoms in the
heme, and the fifth coordination is the axial His-502–iron
bond. The sixth coordination site on the iron ion is vacant and
serves to accept electrons and thereby participate in the elec-
trochemistry of the iron-catalyzed oxidation (43) (Fig. 1A).
The heme inMPO is covalently bound to the protein through
two ester linkages and a methionyl sulfonium linkage (11). In
addition to the three covalent bonds, electrostatic interactions
with pyrrole rings C and D contribute to the structure and sta-
bility of the heme pocket in MPO. The guanidinium group of
Arg-499, as well as that of Arg-590, forms hydrogen bonds with
the carboxyl group of a propionate in ring D (11). Replacement
of Arg-499 with any residue that eliminates this electrostatic
interaction would likely compromise heme binding and stabil-
ity. Furthermore, after arranging the side chains in R499C to
optimize favorable interactions with the molecular neighbors,
the model of the heme pocket predicted sufficient space and
side chain mobility to afford close proximity between its sulfur
atom and the heme iron, if heme were incorporated into the
pocket lacking the stabilizing argi-
nine at 499. Whether in a neutral or
deprotonated state, the sulfur intro-
duced by R499C could coordinate
with the iron, thereby forming a rel-
atively strong interaction at 2.5 Å
(Fig. 1B). Such strong polar or cova-
lent interaction could significantly
compromise redox properties of
the iron ion and thereby compro-
mise the enzymatic activity of the
mutant protein. Thus, the model
predicts two consequences from
R499C, one reflecting the loss of
an important stabilizing electro-
static interaction with arginine
and the other the introduction of a
disruptive cysteine.
The optimized model of G501S
likewise demonstrated potential
changes that could compromise the
function of the heme (Fig. 1C). The
replacement of glycine with serine
may leave inadequate space to stably
accommodate the heme group. Fur-
thermore, if the substitution was
tolerated, replacement of glycine
with serine would reduce the flexi-
bility of the protein backbone in the
heme environs. Although the highly
flexible Gly-501 in native MPO
allows close approximation of the
aromatic nitrogen in His-502 below
the heme iron atom, the loss of flexibility after the serine
replacement might disturb proper heme function. Taken
together, the simplistic models of each of the naturally occur-
ring mutations in such close proximity to the redox center of
MPO predicted structural consequences likely to compromise
optimal function of the heme group.
Failure of G501S Precursor to Undergo Proteolytic Mat-
uration—To examine directly the impact of these missense
mutations on the fate of the protein, we created stable transfec-
tants and compared synthesis of the mutant proteins with that
of normal MPO. Stably transfected K562 cells expressing nor-
mal or G501S MPO were radiolabeled for 1 h and chased for 0
or 20 h before recovery of cells and the conditionedmedium for
immunoprecipitation. K562 transfectants expressing either
normal or G501S MPO synthesized a 90-kDa protein after 1 h
of labeling (Fig. 2). In the case of normal MPO, the 90-kDa
protein underwent proteolytic processing during the 20 h of
chase to yield the 59- and 13.5-kDa subunits of mature MPO.
However, the precursor inG501S cells failed to yield the 59-kDa
heavy subunit, and more of the 90-kDa precursor was present
during the chase period in G501S-expressing cells than in
transfectants expressing normal MPO, indicating that the
absence ofmatureMPO reflected failure to undergo processing
intoMPOsubunits and not the rapid degradation of themutant
G501S precursor.
FIGURE 1. Models of the heme pockets of normal and mutant MPO. A, proximal heme-binding residue,
His-502, and heme iron are depicted in a CPK model. His-502 anchors 6-coordinated Fe3 ion of the heme from
the underneath position, leaving the sixth coordination site above the heme available to react with substrate.
B, normal MPO is depicted in green, R499C in yellow, and bromide (representing the halide-binding site) in
orange. The proximity of the sulfur atom of the cysteine of R499C is sufficient to exert significant electrostatic
effect on the heme iron. C, normal MPO is depicted in green, with G501S in gray. Because of steric limitations,
the replacement of glycine with serine at residue 501 may significantly compromise heme binding. Further-
more, if possible, substitution of the flexible Gly-501 residue with serine would compromise backbone flexi-
bility (backbone “hinge”) in the heme pocket and consequently promote the departure of the His-502 anchor-
ing side chain from the iron ion.
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Normal and G501S-expressing cells secreted the same
amounts of 90-kDaMPOprotein into the culturemedium dur-
ing the chase period (Fig. 2), suggesting that normal amounts of
the G501S precursor entered the secretory pathway despite the
failure of proteolytic maturation to proceed. As reported previ-
ously for normal MPO biosynthesis (20), 10% of MPO pre-
cursor is secreted constitutively and undergoes limited modifi-
cation of its oligosaccharide side chains during transit through
the Golgi, whereby the secreted species is partially resistant to
endoglycosidase H digestion (39). To determine whether the
secreted MPO precursor from transfectants expressing G501S
underwent oligosaccharide modification, the lysates of pulse-
labeled cells and supernatants conditioned by the 20-h chase
period were recovered from each cell line, immunoprecipitated
withMPO antiserum, and subjected to digestion with endogly-
cosidase H orN-glycanase to cleave highmannose or both high
mannose and complex mannose side chains, respectively. The
oligosaccharides on the intracellular 90-kDa MPO precursors
of normal and G501S were both fully susceptible to digestion
with endoglycosidase H, indicating that the side chains were
exclusively high mannose in nature (Fig. 3). However, the car-
bohydrates on the secreted MPO precursor were partially
endoglycosidase H-resistant, as evidenced by limited digestion
with endoglycosidase H but complete removal by N-glycanase
treatment. The G501Smutant behaved in a fashion identical to
that of normal MPO, suggesting that the G501S precursor
entered the constitutive secretory pathway andwasmodified by
Golgi resident enzymes in a normal fashion.
During normal biosynthesis MPO precursors interact tran-
siently with calreticulin (CRT), calnexin (CLN), and ERp57
(20), all molecular chaperones in the ER that contribute to the
proper folding of many glycoproteins (44). Pulse-labeled K562
cells transfected with normal or G501SMPOwere chased for 0,
1, 2, or 4 h, and the lysates were immunoprecipitated in parallel
with antibodies againstMPO,CRT, or CLNunder nondenatur-
ing conditions, as described previously. To recover the CRT-
and CLN-associated MPO precursor at each time point, the
immunoprecipitates were denatured and subjected to a second
immunoprecipitation using theMPO antibody (Fig. 4). In both
transfectants expressing normal and G501SMPO, the recover-
ies of CRT-associated and CLN-associated MPO precursor
were the same as reported previously for normal MPO (24, 26),
suggesting that the interactions between CRT or CLN with
MPO precursors were not significantly altered by the G501S
missense mutation.
Activity of G501S Precursors Expressed in K562 Cells—Nor-
mal MPO biosynthesis requires the insertion of heme into
apopro-MPO in the ER, thereby converting an enzymatically
inactive 90-kDa MPO precursor into a 90-kDa protein with
peroxidase activity (45). We assessed first the peroxidase activ-
ity of the G501S product spectroscopically using o-dianisidine
as the substrate. K562 cells lack endogenous MPO (18) and
exhibited very low background peroxidase activity in this assay
(0.9 IU). In contrast, an identical number of PLB-985 cells, a
human promyelocytic cell line that actively synthesizes struc-
turally and functionally normal MPO (24), had 17.2 IU of per-
oxidase activity. K562 cells transfected with normal MPO had
4.9 IU of peroxidase activity (n  5), whereas G501S transfec-
tants had 0.5 IU of activity, levels indistinguishable from base
line. Because we were concerned that the relatively low effi-
ciency ofMPOexpression in theK562 cell systemmight under-
mine our capacity to detect very low levels of activity by the
G501S, we examined the suitability of using HEK cells for bio-
synthetic studies, based on its successful application to gener-
ating recombinant protein for use in immunological character-
ization of anti-MPO-mediated vasculitis (46).
MPO Biosynthesis by HEK Transfectants—Wild-type HEK
cells lack endogenous MPO, but after transfection synthesized
FIGURE 2. Biosynthesis of normal and G501S MPO by transfected K562
cells. K562 cells stably transfected with wild-type MPO (WT) or G501S mutant
MPO (G501S) were pulse-labeled with [35S]methionine and chased for 0 or
20 h. Cell lysates at 0 and 20 h and culture medium at 20 h were immunopre-
cipitated with anti-MPO. Immunoprecipitates were separated by SDS-PAGE,
and dried gels were subjected to autoradiography. Cells expressing G501S
synthesized and secreted a 90-kDa precursor form of MPO but failed to proc-
ess it into the mature MPO, represented by the generation of the 59-kDa
heavy subunit of the native protein.
FIGURE 3. Glycosylation of normal and G501S MPO produced by K562
transfectants. After 1 h of biosynthetic pulse labeling with [35S]methionine
and a 20-h chase, cell lysates and culture medium from K562 cells expressing
normal (WT) or mutant (G501S) MPO were immunoprecipitated with anti-
MPO. Immunoprecipitates were incubated with buffer alone (C), endoglyco-
sidase H (H), or N-glycanase (N) before recovery and analysis by SDS-PAGE and
autoradiography. Fully glycosylated precursor migrated at 90 kDa, whereas
the nonglycosylated product was 80 kDa. Arrows indicate individual glyco-
sylated products. For both normal and mutant MPO, secreted MPO precur-
sors were more resistant to endoglycosidase H digestion than were the intra-
cellular forms.
FIGURE 4. Association of molecular chaperones with normal and G501S
MPO in K562 cells. K562 transfectants expressing normal (wild type) or G501S
MPO were biosynthetically radiolabeled for 1 h and chased with cold methi-
onine for 0 – 4 h. Cell lysates were immunoprecipitated with anti-MPO or
sequentially with anti-CRT or anti-CLN followed by anti-MPO. Resulting
immunoprecipitates were analyzed by SDS-PAGE and autoradiography. Like
normal MPO, the G501S precursor associated transiently with CRT and CLN.
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heme-containing precursors that underwent normal proteo-
lytic processing to mature MPO and efficient targeting to an
intracellular, membrane-bound compartment that could be
pelleted by centrifugation (Fig. 5). All aspects of MPO biosyn-
thesis seen in cultured myeloid cells were reproduced in the
HEK-MPO system. Specifically, the 90-kDa apopro-MPO
acquired heme in the ER to form pro-MPO and precursors
interacted with molecular chaperones ERp57, CRT, and CLN
(Fig. 6) with the same selectivity previously reported for the
K562 transfectants (24, 26). Heme acquisitionwas necessary for
exit from the ER and for proteolytic processing to mature sub-
units, with the latter event inhibited by disruption of the Golgi
by treatmentwith brefeldinA (data not shown). Approximately
10% of MPO precursor entered the secretory pathway and
underwent limited modification of its oligosaccharide side
chains, as seen with MPO endogenously produced by cultured
promyelocytes (39). The spectral properties of MPO-enriched
pellets recovered from stable transfectants were identical to
those of normalMPO (see below), with a max of 430 nm for the
oxidized sample and a Soret band at 473 nm for the reduced
minus oxidized spectroscopy (41). Taken together, the data
indicate that the HEK transfectants faithfully mirrored the
events in normal MPO biosynthesis previously identified in
myeloid precursors.
Most important for our studies was the improved level of
MPO expression in HEK cells relative to that in the K562 trans-
fectants. Wild-type HEK cells lack any evidence of endogenous
MPO, as judged immunochemically, spectroscopically, or by
assessing enzymatic activity. In contrast, the specific activity of
HEK-MPO (4.2 nmol of H2O2 consumed per min/pmol MPO,
n  3) was the same as partially purified MPO recovered from
granules of normal PMN (3.3 nmol ofH2O2 consumedpermin/
pmol MPO, n  3) or the human promyelocytic cell line PLB-
985 cultured inhemin (3.6nmolofH2O2consumedpermin/pmol
MPO, n  3). Although the amount of MPO in transfectants (3.9
pmolofMPO/106 cells,n3)was lower than that innormalPMN
(11.7 pmol of MPO/106 cells, n  3) or in PLB-985 cells grown in
the presence of hemin (11 pmol of MPO/106 cells, n  3), HEK
transfectants provided a system to yield levels of protein sufficient
to perform spectroscopy and reliably assess function of specific
mutants.
HEK-R499C, a Second Mutation Near the Critical Proximal
Histidine in the Heme Pocket—To assess the impact of the
R499C missense mutation on MPO biosynthesis both in rela-
tion to normal MPO and to G501S, we created stably trans-
fected HEK cell lines expressing the mutant forms of MPO.
After 1 h of biosynthetic labeling with [35S]methionine, HEK-
R499C associated with CRT, CLN, and ERp57 to the same
extent as did wild-type MPO (Fig. 6), and the rates of dissocia-
tion during the chase were likewise the same (data not shown).
Both R499C and G501S lacked enzymatic activity in native
activity gels (Fig. 7). The HEK-R499C resembled G501S with
respect to proteolytic processing, as both mutations resulted in
synthesis of a 90-kDa species that was secreted normally but
was not processed into mature subunits after a 20-h chase (Fig.
8A). As both mutants were enzymatically inactive and failed to
undergo normal maturation, we anticipated that neither incor-
porated heme. However, transfectants expressing normal or
mutant MPO and labeled with -[14C]aminolevulinic acid, a
precursor of heme, synthesized the 90-kDa pro-MPO that was
released into the culture medium (Fig. 8B). When normalized
for the [35S]methionine content in MPO precursors, heme
incorporation was 28.7  2.9 and 23.7  1.6% of control for
R499C andG501S, respectively (n 3). Based on these data and
the amount of heme inHEK-MPO cells (3.9 pmol/106 cells), we
estimate that R499C and G501S transfectants contained 1.12
and 0.92 pmol of heme-containing MPO-related protein per
106 cells. Thus, in bothmutants therewas amaturation arrest at
the stage of heme incorporation, whereby heme acquisition by
mutant apopro-MPO was inefficient or the mutant pro-MPO
was unstable and rapidly degraded. The stability of the mutant
precursors was not increased by culturing cells in the presence
of proteasome inhibitors (data not shown), in contrast to the
FIGURE 5. Biosynthesis of normal MPO by stably transfected HEK cells.
Wild-type HEK cells (WT) or HEK cells stably expressing normal MPO were
biosynthetically radiolabeled, with intervals of chase of 0 and 20 h. Cell lysates
and culture medium were immunoprecipitated with anti-MPO and the
immunoprecipitates analyzed by SDS-PAGE and autoradiography. Wild-type
HEK cells lacked endogenous MPO. When expressed in HEK cells, MPO pre-
cursors were synthesized, secreted, and proteolytically processed intracellu-
larly in a fashion identical to that seen in myeloid cells expressing endoge-
nous MPO.
FIGURE 6. Association of molecular chaperones with normal MPO in sta-
bly transfected HEK cells. Stably transfected HEK cells expressing normal
(wild-type MPO) or R499C mutant were biosynthetically radiolabeled for 1 h
and immunoprecipitated with anti-MPO or antibodies against the molecular
chaperones CRT, CLN, or ERp57 under nondenaturing conditions. Immuno-
precipitates were analyzed by SDS-PAGE and autoradiography. Molecular
chaperones coprecipitated with precursors of normal and mutant MPO
(results representative of three independent experiments).
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proteasome-mediated degradation seen with the MPOmutant
Y173C (17), indicating that if degradation of mutant proteins
occurred, it was not mediated by the proteasome.
Given the failure of eithermutant to exhibit peroxidase activ-
ity in vitro, we anticipated that neither would chlorinate tau-
rine. Neither G501S nor R499C chlorinated taurine (data not
shown), and the capacity forG501S or R499C to consumeH2O2
was low, 0.52 and 0.65 nmol/min/cell eq, respectively, and no
different from that of wild-type HEK cells (0.91 nmol/min/cell
eq). In contrast, HEK transfectants expressing normal MPO
were fully active (5.75 nmol/min/cell eq), suggesting that
although themutant had incorporated heme, the resultant pro-
MPOwas not competent tomediate
peroxidative events. To compare
the spectral properties of normal
and mutant proteins, samples
enriched for the intracellular com-
partment in HEK cells containing
normal and mutant MPO were pre-
pared. The presence of MPO-re-
lated proteins in each pellet was
confirmed by immunoblotting (data
not shown). Although all four sam-
ples had identical spectra in the
200–400 nm range (data not
shown), significant differences were
noted in the Soret absorbance
region. Wild-type HEK cells lacked
a Soret peak between 400 and 500
nm (Fig. 9), whereas the pellets
recovered from normal PMN or
from HEK transfectants expressing
normal MPO exhibited a peak at
430 nm, characteristic of MPO (41).
In contrast, pellets from HEK transfectants expressing R499C
or G501S exhibited a Soret band at 414 nm, with no detectable
signal at 430 nm. The observed red shift of the absorbance peak
in themutant proteins suggests that each of the alterations near
histidine 502, critical for binding on the proximal side of the
heme, altered the structural conformation of the heme.
DISCUSSION
Mature MPO normally resides exclusively in the azurophilic
granules of PMN and monocytes, compartments containing a
variety of hydrolytic enzymes (for review of MPO biology see
Ref. 1). Concomitant activation of the NADPH-dependent oxi-
dase, a source of reactive oxygen species including H2O2, and
release of granule contents, including MPO, into the newly
formed phagolysosome, deliver to the ingested microorganism
a variety of toxic reactants that synergistically mediate efficient
killing (reviewed in Ref. 3). Among these noxious agents is
HOCl, the result of the unique property ofMPO to catalyze the
2-electron peroxidation of Cl in the presence of H2O2 (47).
HOCl is extremely toxic to bacteria; 108 HOCl molecules/cell
can kill 5 g of Escherichia coli, whereas 1011 molecules of
H2O2 (under metal-free conditions) or hydroxyl radical are
necessary to achieve the same cytotoxicity (48–50). Several
lines of evidence support the importance of the MPO-H2O2-
Cl system in oxygen-dependentmicrobicidal activity against a
wide spectrum of organisms, including viruses, bacteria, fungi,
protozoa, and tumor cells as well as promoting inflammation
per se (reviewed in Ref. 47). Given that MPO and its unique
chemistry appear especially well suited for a central role in anti-
microbial activity, elucidation of critical structural determi-
nants is essential to understand the basis for its biological
action.
Heme peroxidases can be categorized into three superfami-
lies based on sequence: catalases, plant peroxidases, and mam-
malian peroxidases (51). Mammalian peroxidases include the
cyclooxygenase and myeloperoxidase families, the latter com-
FIGURE 7. Peroxidase activity of R499C MPO. Wild-type HEK cells, HEK cells stably transfected with R499C or
normal MPO (MPO), or purified MPO (2 g) were separated in two identical native gels. Resultant gels were
stained for peroxidase activity (A) or electroblotted to nitrocellulose and probed with anti-MPO (B). No perox-
idase activity was identified in HEK cells or in R499C-HEK cells, whereas HEK-MPO cells exhibited peroxidase
activity (A). The lack of activity in R499C-HEK cells did not reflect the absence of the mutant protein from the gel,
as demonstrated by the presence of immunoreactive protein in the R499C-HEK cell immunoblot (B).
FIGURE 8. Biosynthetic incorporation of heme into normal, R499C, and
G501S MPO. HEK transfectants expressing normal MPO, R499C, or G501S
were pulse-labeled with [35S]methionine and chased for 20 h (A) or labeled
with -[14C]aminolevulinic acid (B). The resultant cell lysates and culture
media were immunoprecipitated with anti-MPO and analyzed by SDS-PAGE
and autoradiography. Given the relative specific activities of the radioiso-
topes used, autoradiographs were exposed for 6 h or 11 days for 35S and 14C,
respectively. Although heme was incorporated into the 90-kDa pro-MPO and
59-kDa mature subunit in HEK-MPO cells, heme acquisition for G501S and
R499C was limited to the mutant 90-kDa pro-MPO form. When normalized for
the amount of [35S]methionine-labeled MPO precursor, heme incorporation
for G501S and R499C was 23.7  1.6 and 28.7  2.9% of that for normal MPO.
Values represent mean  S.E., n  3.
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posed of MPO, eosinophil peroxidase (EPO), lactoperoxidase
(LPO), and thyroid peroxidase (TPO) (52, 53). These peroxi-
dases share the unique property of having two or three covalent
bonds between the heme and the mature enzyme. Availability
of an expression system for MPO biosynthesis and processing
that faithfullymirrors the endogenous events inmyeloid cells is
an analytical tool necessary for the study of structure-function
relationships in the heme pocket of animal peroxidases. Previ-
ous studies of the structural features of the heme environment
ofMPO that employedmutagenesis (reviewed in Ref. 54) relied
on recombinant protein isolated from transfectants unable to
synthesize the functional, normal subunits of MPO. The
recombinant MPO produced in Chinese hamster ovary cells
used for these studies has oligosaccharide side chains signifi-
cantly different from native MPO, fails to undergo proteolytic
processing into mature subunits, and is expressed only in the
monomeric form (55). Such differences may have functional
consequences. For example, mutation of Met-409 to the corre-
sponding residue in EPO (Thr), TPO (Val), or LPO (Gln)
altered the spectral properties of the recombinant protein and
eliminated its peroxidase activity (56), an unexpected finding
given that this replacement normally exists in these related per-
oxidases. Given the quality control operative in the ER during
MPO biosynthesis (17, 57, 58), it is possible that the observed
deviations from normal biosynthesis have structural conse-
quences thatmay undermine the interpretation of studies using
the Chinese hamster ovary-derived recombinant protein.
Although K562 transfectants expressing normal MPO reca-
pitulate biosynthetic events seen in myeloid cells expressing
endogenousMPO, the yields of recombinant protein are insuf-
ficient for structural or functional studies. As an essential com-
ponent of this study, we established that HEK cells stably trans-
fected with normal MPO exhibited seminal features of the
biosynthesis and proteolytic processing ofMPO as first charac-
terized in myeloid precursors (reviewed in Ref. 17 and see Refs.
18, 24, 26, 28, 30, 31, 57, 59–63). The primary translation prod-
uct in HEK cells underwent cotranslational cleavage of the sig-
nal peptide, N-linked glycosylation, and limited deglucosyla-
tion of high mannose oligosaccharide side chains to generate
the 90-kDa, enzymatically inactive precursor apopro-MPO that
interacted in the ER transiently and reversibly with the molec-
ular chaperones ERp57, CRT, and CLNwith subsequent incor-
poration of heme to generate the enzymatically active 90-kDa
pro-MPO. Heme synthesis inhibition blocked proteolytic mat-
uration as well as export of MPO precursor from the ER, indi-
cating that its acquisition of heme induced conformational
changes necessary for successful maturation and intracellular
targeting. Although 10% of pro-MPO entered the secretory
pathway andwas recovered from the culturemedia, as reported
for myeloid cells (64, 65), most pro-MPO underwent modifica-
tion of oligosaccharide side chains and proteolytic processing
en route to a membrane-bound intracellular compartment.We
believe that our expression system provides sufficient material
that mirrors the native protein and is thus especially well suited
to address several specific questions of structure-function rela-
tionships raised by its crystal structure.
Among the animal peroxidases, only MPO has been crystal-
lized, with structures of both the human and canine enzyme
published. Based on the crystal structure of humanMPO at 1.8
Å (11), the heme pocket is in a crevice 15–20 Å deep and is
solvent-accessible via an open channel at the catalytic site on
the distal side of the heme (53). There is significant amino acid
identity among the animal peroxidases in the four helices that
surround the heme group, and several lines of evidence (4,
66–68) implicate five residues in binding heme inMPO. Histi-
dines at residues 261 and at 502 represent the distal and prox-
imal ligands, respectively, and heme is covalently bound to
MPO at three sites as follows: through a methionyl sulfonium
linkage with Met-409 and through ester linkages to Glu-408
and Asp-260 (11, 69). The heme-protein interaction is further
stabilized by hydrogen bonding between the carbonyl groups of
ring C andD propionates and Thr-266, Asp-264, Arg-499, Arg-
590, and water molecules (11). Although crystal structures for
other family members have not been solved, modeling of
homologous domains, NMR, mass spectrometry, and peptide
analysis support the presence of the same two ester linkages in
LPO, EPO, and TPO (11, 70–74). Ester bonds account for the
10 nm shift in the Soret band of LPO, EPO, and TPO relative to
horseradish peroxidase, and the presence of the third covalent
bond in MPO causes the red shift of the Soret band of oxidized
MPO (max 430 nm) relative to the spectral peak for the other
family members (max  412 nm) (73, 75, 76). The peculiar
sulfonium linkage in MPO likely contributes as well to its
unique facility to oxidize Cl to HOCl at physiologic pH. The
presence of covalent bonds between the prosthetic group and
the protein is a feature unique to the animal peroxidases (51),
and a H2O2-dependent autocatalytic process has been impli-
cated in ester bond formation (72), although the precise mech-
anisms of ester bond formation in animal peroxidases and of
sulfonium linkage in MPO in vivo are unknown. Although at
least one covalent bond is required for peroxidase activity and
the presence of covalent bonds with heme is a feature shared by
FIGURE 9. Spectral properties of normal and R499C MPO. The 48,000  g
pellet recovered from wild-type (WT) HEK cells or from HEK cells stably
expressing normal MPO or the R499C mutant was scanned spectrophoto-
metrically. Whereas pellets from wild-type HEK lysates lacked a Soret band,
cells expressing normal MPO exhibited the 430 nm peak characteristic of
MPO. In contrast, the peak from R499C-HEK cells was shifted to 414 nm. Spec-
tra are representative of three independent experiments.
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all animal peroxidases, the functional or biological advantage of
covalently bound heme is not known (73). Recent studies indi-
cate that the presence of a single covalent bond between the
heme group and its protein is sufficient to protect the heme
vinyl group frommodification by hypohalous acid generated
by peroxidases (77–79). In this way, peroxidases such as
MPO can generate large amounts of HOCl and its by-prod-
ucts within the neutrophil phagosome without incurring
autoinactivation by modification of the heme vinyl groups
and subsequent inactivation.
In this study we describe the impact of two novel mutations
on the biosynthesis and function of human MPO. The target
residues,Gly-501 andArg-499, are present on the proximal side
of the hemepocket and are conserved in all fourmembers of the
animal peroxidase family. Although both missense mutations
compromised proper proteolytic processing and intracellular
targeting ofmatureMPO, the precursors for each incorporated
heme, albeit inefficiently. Both biosynthetic radiolabeling of
heme (Fig. 8) and spectroscopy (Fig. 9) demonstrated the pres-
ence of small amounts of heme in the proproteins of G501S and
R499C.However, the Soret bandwas blue-shifted in each, dem-
onstrating a spectrum more akin to that seen with LPO, TPO,
or EPO rather than that characteristic of nativeMPO.Although
the spectra of the mutants were consistent with the presence of
heme covalently bound, likely via two rather than three bonds,
neither had enzymatic activity. Given the known electrostatic
interaction between Arg-499 and the ring D propionates of the
heme inMPO,we predicted that the loss of this critical arginine
would itself compromise heme binding and stability. Further-
more, the presence of cysteine at this site might allow a strong
polar or covalent interaction between the sulfur atom in Cys-
499 and the heme iron, which could reduce the oxidation
potential and enzymatic activity of themutantMPO. In the case
of changes at codon 501, glycine may be the only amino acid at
that site that allows optimal heme binding, consistent with our
spectral data indicating incorporation of only small amounts
of heme. For any serine that is incorporated in the heme
pocket, our modeling of G501S suggested that its dysfunc-
tion reflects the increased distance between the heme iron
and its distal histidine at 502, which is predicted to be twice
that present in normal MPO, consistent with the loss of one
coordination site for the heme iron, as suggested experimen-
tally by the spectroscopy.
Taken together, these studies of biosynthesis and biochemi-
cal characterization of mutant MPO expressed in HEK cells
demonstrated the structural and functional impact of two nat-
urally occurring missense mutations underlying hereditary
myeloperoxidase deficiency. Future applications of these ana-
lytical techniques to other mutations, both experimentally cre-
ated and spontaneously occurring, should provide novel
insights regarding the structure-function relationships unique
to the animal peroxidase protein family.
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